OraSure Technologies Inc. (NASDAQ:OSUR) shot up 9.6% during mid-day trading on Monday . The company traded as high as $8.60 and last traded at $8.60, with a volume of 2,308,350 shares. The stock had previously closed at $7.85.

A number of brokerages recently issued reports on OSUR. Mizuho reissued a “buy” rating and set a $8.00 price target on shares of OraSure Technologies in a research report on Friday, May 6th. BTIG Research reaffirmed a “buy” rating on shares of OraSure Technologies in a report on Wednesday, August 24th. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, May 25th. Jefferies Group reduced their target price on OraSure Technologies from $8.50 to $8.00 and set a “buy” rating on the stock in a report on Thursday, August 4th. Finally, TheStreet downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Friday, July 1st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $8.25.

The stock has a market capitalization of $481.50 million and a P/E ratio of 41.24. The company’s 50-day moving average price is $6.85 and its 200 day moving average price is $6.92.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. During the same period last year, the firm posted $0.03 EPS. The company earned $31.36 million during the quarter, compared to the consensus estimate of $31.15 million. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. On average, equities analysts predict that OraSure Technologies Inc. will post $0.27 earnings per share for the current fiscal year.

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.